Agenda

- Welcome
- Kentucky COVID-19 Updates
- Pediatric Vaccine Update - 6 months to 4 years old
- Are You “Up To Date”?
- Pediatric Vaccination and Fertility – Dr. Shannon Clark
- Q & A
mRNA Primary Series and Boosters in Moderately or Severely Immunocompromised

- Twenty-eight (28) days after receipt of the initial 2 dose series (Moderna or Pfizer), individuals should receive 1 additional dose to complete the primary series (3 doses)
  - Pfizer 5 years old and older
  - Moderna 18 years old and older

- Booster doses are recommended for individuals 12 years of age and older after completion of primary series.
  - The booster dose is recommended at least 3 months after the third dose in the primary series, for a total of four doses.
    - Preferably with an mRNA COVID-19 vaccine.
    - If Moderna vaccine is used for the booster dose, a 50 mcg (0.25 mL) dose should be used. Individuals that are immunocompromised will receive four (4) total doses.
A primary Janssen vaccine dose is authorized for people ages 18 years and older who are moderately or severely immunocompromised.

The primary vaccine dose should be followed by a second (additional) dose using an mRNA COVID-19 vaccine at least 4 weeks later to complete the primary series.

- If Moderna COVID-19 vaccine is used for the second dose, administer a 100 mcg (0.5 ml) dose.
  - 1 Janssen + 1 mRNA=2 doses
Janssen Primary Series and Boosters in Moderately or Severely Immunocompromised

A single booster dose is recommended at least 2 months after the 2nd (additional) dose of the primary series, for a total of 3 doses

- 1 Janssen vaccine dose + 1 mRNA vaccine dose + 1 booster dose
  - mRNA vaccines are preferred for the booster dose.
- If the Moderna vaccine is used for the booster dose, a 50 mcg (0.25 ml) dose should be used.
Many recipients of Janssen COVID-19 vaccine may have already received a booster dose (Pfizer-BioNTech, Moderna [50 mcg, 0.25 ml], or Janssen vaccine), without having had the 2nd (additional) mRNA vaccine dose.

In this situation, regardless of type and timing of vaccine received as the 2nd dose
- administer a Pfizer-BioNTech vaccine or a Moderna vaccine (100 mcg [0.5 mL]) as the 3rd dose at least 2 months after dose 2.

Helpful link: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#vaccination-people-immunocompromised
Vaccines and Monoclonal Antibodies

➢ People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time;

➢ COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma